Document Detail


Idarubicin oral: new formulation. No proven benefit over 60.
MedLine Citation:
PMID:  11067717     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
(1) Oral idarubicin is marketed in France for the treatment of acute myeloblastic leukaemia in patients over 60 who are ineligible for intensive intravenous treatment. (2) The clinical file on oral idarubicin is limited. (3) In non comparative trials the median survival time after starting treatment with oral idarubicin, alone or combined with other cytotoxic agents, did not exceed 12 months. (4) The only comparative trial of single-agent idarubicin in this indication gave unfavourable results. Another comparative trial tested a combination comprising idarubicin, but the role of idarubicin alone cannot be determined from the results. (5) In the palliative care setting the clinical efficacy of oral idarubicin has not yet been demonstrated. (6) The main adverse events observed during oral idarubicin therapy are neutropenia, thrombocytopenia, nausea and vomiting, diarrhoea and hair loss. Their impact on patients' quality of life has not been adequately assessed.
Authors:
-
Related Documents :
23331347 - Making the case for primary care and mandated suicide prevention education.
22957957 - Neurocognitive diagnostic challenges and the dsm-5: perspectives from the front lines o...
24011497 - Interactive technology in obstetric anaesthesia and analgesia: exploring seamless solut...
23400317 - Teleneurology applications: report of the telemedicine work group of the american acade...
18838567 - Standards for measures used for public reporting of efficiency in health care: a scient...
3826107 - Cecal perforation following fiberoptic flexible sigmoidoscopy.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Prescrire international     Volume:  9     ISSN:  1167-7422     ISO Abbreviation:  Prescrire Int     Publication Date:  2000 Aug 
Date Detail:
Created Date:  2000-10-26     Completed Date:  2000-10-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9439295     Medline TA:  Prescrire Int     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  103-5     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Antibiotics, Antineoplastic* / administration & dosage,  adverse effects,  therapeutic use
Clinical Trials as Topic
Drug Approval
France
Humans
Idarubicin* / administration & dosage,  adverse effects,  therapeutic use
Leukemia, Myeloid, Acute / drug therapy*,  mortality
Middle Aged
Survival Rate
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 58957-92-9/Idarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ceftriaxone and otitis in children: new indication. Only in special circumstances.
Next Document:  Pneumococcal vaccination for elderly subjects: license extension. Still no proof of clinical efficac...